Fongémie à Saccharomyces boulardii chez un brûlé grave

Viggiano, M.; Badetti, C.; Bernini, V.; Garabedian, Matthew; Manelli, J.C.

doi:10.1016/s0750-7658(05)80603-3

Cited by 41 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fungemia caused by S. cerevisiae subtype boulardii should not be considered rare. To our knowledge, 24 well-described clinical cases have been reported in the literature (1,3,4,6,7,9,10,(13)(14)(15)(16) (Table 1). In a further report, 12 (93%) of 13 S. cerevisiae blood isolates collected in five hospitals over a 2-year period were retrospectively subtyped as S. cerevisiae subtype boulardii, and their etiologic role in fungemias was demonstrated by a genotypic comparison with commercial preparations labeled S. boulardii (12).…”

Section: Case 4 (Incomplete Report)mentioning

confidence: 99%

Outbreak of Saccharomyces cerevisiae Subtype boulardii Fungemia in Patients Neighboring Those Treated with a Probiotic Preparation of the Organism

et al. 2003

View full text Add to dashboard Cite

We report an outbreak of Saccharomyces cerevisiae subtype boulardii fungemia among three intensive care unit roommates of patients receiving lyophilized preparations of this fungus. The fungemia was probably due to central venous catheter contamination and resolved after fluconazole treatment. The need for stringent application of proper hygiene when using a probiotic preparation of this organism is emphasized. CASE REPORTSOutbreak cases. (i) Case 1. Case 1 involved a 34-year-old man hospitalized for hypoxia after head and thoracic trauma. He was placed on enteral nutrition, with insertion of a central venous catheter (CVC), and broad-spectrum antibiotic therapy was administered. On day 42 after admission (5 November 2000), he developed a fever, which was unsuccessfully treated with teicoplanin and imipenem. Multiple blood cultures yielded Saccharomyces cerevisiae. The fever and fungemia subsided under treatment with fluconazole at 400 mg/day. The CVC was removed 3 weeks after initiation of fluconazole treatment. The infectious episode resolved, but no catheter culture was performed.(ii) Case 2. Case 2 involved a 48-year-old man hospitalized for rupture of a cerebral aneurysm and fever. He was given enteral nutrition, and a CVC was inserted. Teicoplanin alone and then teicoplanin and meropenem were administered. On day 14 (10 November 2000), one blood culture yielded S. cerevisiae. On day 19, the CVC was removed and fluconazole therapy (400 mg/day) was immediately started. No catheter culture was performed. The fever subsided within 48 h of the initiation of fluconazole treatment.(iii) Case 3. Case 3 involved a 75-year-old woman admitted for acute myocardial infarction. She was given enteral nutrition, and a CVC was inserted. She was treated with various antibiotic regimens for several febrile episodes. On day 56 (10 April 2001), a blood culture yielded S. cerevisiae. The CVC was removed, leading to immediate defervescence. The CVC tip was positive for S. cerevisiae. Fluconazole therapy (400 mg/day) was started 2 days later and administered for 2 weeks.None of the three patients described above received any probiotic treatment. Case 4 (incomplete report).A 35-year-old woman with multiple traumas who had been hospitalized in the intensive care unit (ICU) at the same time as patients 1 and 2 had blood cultures positive for S. cerevisiae. Unfortunately, her medical record was sequestered for forensic purposes and whether she had received probiotic treatment or not could not be determined. This patient improved and was transferred to the orthopedic division, from which she was discharged 2 months later.The outbreak setting was an eight-bed ICU in a 400-bed secondary-care hospital in Rome, Italy. During the year preceding the outbreak, about 20% of the ICU patients were hospitalized for emergency surgery, 12% were hospitalized for elective surgery, 18% were hospitalized for trauma, and 50% were hospitalized for medical diseases. The mean (Ϯ standard deviation) age of patients was 66 Ϯ 16 years, the mean ICU hospitali...

show abstract

Section: Case 4 (Incomplete Report)mentioning

confidence: 99%

Outbreak of Saccharomyces cerevisiae Subtype boulardii Fungemia in Patients Neighboring Those Treated with a Probiotic Preparation of the Organism

et al. 2003

View full text Add to dashboard Cite

show abstract

“…In our knowledge, there is not any literature review to identify previously reported pediatric cases of S. cerevisiae. We searched for “ S. cerevisiae ” and “fungemia” in the Pubmed database and found 15 suitable pediatric cases of S. cerevisiae fungemia [ [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] ]. Adult (>18 years) cases and cases with insufficient clinical information were excluded from this review.…”

Section: Discussionmentioning

confidence: 99%

Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature

Atıcı

Soysal

Cerit

et al. 2017

Medical Mycology Case Reports

View full text Add to dashboard Cite

Although Saccharomyces boulardii is usually a non-pathogenic fungus, in rare occasions it can cause invasive infection in children. We present the case of an 8-year-old patient in pediatric surgical intensive care unit who developed S. cerevisiae fungemia following probiotic treatment containing S. boulardii. Caspofungin was not effective in this case and he was treated with amphotericin B. We want to emphasize that physicians should be careful about probiotic usage in critically ill patients.

show abstract

“…Alguns fatores estavam presentes nestes pacientes como precárias condições gerais, provável lesão da mucosa intestinal devido a desnutrição, diarréia crônica, isquemia intestinal, uso de antibióticos de largo espectro alterando a microbiota intestinal e altas doses do probiótico. Dentre estes casos, três ocorreram em crianças: uma com grave queimadura (55%) com infecção do trato urinário por E. faecium 81 ; um lactente de 1 ano de idade com diarréia protraída, desnutrição grave e broncopneumonia 80 ; outro lactente de 20 meses de idade com síndrome do intestino curto, história recente de septicemia, recebendo Saccharomyces boulardii durante 11 meses 79 . Entre os quatro adultos, um paciente estava colectomizado e apresentava história recente de choque séptico 82 ; dois eram HIV-positivos, imunossuprimidos com catéteres venosos centrais 78 , e um paciente desenvolveu fungemia após recuperação de parada cardíaca e isquemia de mucosa intestinal 77 .…”

Section: Ensaios Clínicosunclassified